About AVT
Browse Articles
Authors
Customer Services

From the first issue of Volume 26 (2021) Antiviral Therapy will be published by SAGE Publishing.

Please note that the journal is running later than expected due to COVID-19.

During the transition, you can still access content to which you have subscribed via the AVT website. Content will be available to access via the SAGE Journals platform in Summer 2021. https://uk.sagepub.com/en-gb/eur/antiviraltherapy.

If you have any questions relating to the transfer, please contact journaltransitions@sagepub.com

From the first issue of Volume 26 (2021) Antiviral Therapy will be published by SAGE Publishing.

Subscriptions Please note that Antiviral Therapy is running later than expected due to COVID-19.

All subscription queries should be sent to subscriptions@sagepub.co.uk

Orders via subscription agents
If you are using a subscription agent, please instruct your agent as usual. We are notifying all subscription agents of this change of publisher and they will be able to handle your query.

Pricing enquiries 2021 Antiviral Therapy pricing set by International Medical Press will be honoured.

From the first issue of Volume 26 (2021) Antiviral Therapy will be published by SAGE Publishing.

Please continue to submit your manuscripts to the AVT ScholarOne site (https://mc.manuscriptcentral.com/avt)

For papers already in peer-review, you will be informed of a decision as soon as possible. All accepted papers not assigned to a 2020 issue will now be published by SAGE.

Author Guidelines

Antiviral Therapy is an international, peer-reviewed journal devoted to publishing articles on the clinical development and use of antiviral agents, and the treatment of all viral diseases.

Our journal publishes original articles, reviews, editorials, correspondence, short communications and case reports. All manuscripts are submitted through our online ScholarOne Manuscripts™ portal and undergo a thorough peer-review, headed by a team of expert Section Editors

To facilitate the peer-review process and ensure a timely decision, Antiviral Therapy requests that authors are familiar with our Author Guidelines before submitting.

In addition to our Author Guidelines, Antiviral Therapy encourages authors to adhere to the guidelines on good publication practice from the Committee on Publication Ethics (COPE).

Copyright © 2021 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.